Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$58.41 USD

58.41
7,860,150

-0.62 (-1.05%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $58.42 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

by Ekta Bagri

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.

AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate

by Zacks Equity Research

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.

AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq

by Zacks Equity Research

FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.

Incyte (INCY) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels

by Kinjel Shah

The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.

Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.

Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug

by Zacks Equity Research

Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.

AbbVie's (ABBV) Rinvoq Gets Approval for Eczema in Europe

by Zacks Equity Research

AbbVie's (ABBV) European approval for Rinvoq for atopic dermatitis marks the fourth EC-approved indication for the JAK inhibitor drug.

Pfizer (PFE) Xeljanz Gets EC Nod for Kids Psoriatic Arthritis

by Zacks Equity Research

With the approval for polyarticular JIA and juvenile PsA, Pfizer's (PFE) Xeljanz is now approved for four indications in Europe.

Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.

Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth

by Zacks Equity Research

Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.

Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.

Incyte (INCY) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 10.96% and 2.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More

by Kinjel Shah

Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.

Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

by Zacks Equity Research

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?

by Zacks Equity Research

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.

Earnings Preview: Incyte (INCY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REGN or INCY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

REGN vs. INCY: Which Stock Is the Better Value Option?

AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA

by Zacks Equity Research

The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.

Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA

by Zacks Equity Research

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion

by Zacks Equity Research

Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

REGN vs. INCY: Which Stock Is the Better Value Option?

by Zacks Equity Research

REGN vs. INCY: Which Stock Is the Better Value Option?

AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA

by Zacks Equity Research

The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.